Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Part of paid clinical trials in Bellaire, Texas.
- Sponsor
- Regeneron Pharmaceuticals
- Study ID
- NCT05989126
- Phase
- PHASE3
- Status
- Completed
Conditions
- Diabetic Macular Edema (DME)
- Neovascular Age-Related Macular Degeneration (nAMD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- aflibercept 8 mg PFS — DRUGSterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection
Study Details
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the need for the retina specialist to prepare the injection syringe from a separate vial. This Phase IIIb study is focused on patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). The main aim of the study is to evaluate if the 8 mg aflibercept PFS allows for successful preparation and administration of 8 mg aflibercept by retina specialists. The study will also assess the safety of 8 mg aflibercept PFS use. Regeneron will use the information from the study to better understand if the PFS can be used safely and effectively by retina specialists to administer 8 mg aflibercept.
Key Dates
- Start date
- Apr 15, 2024
- Status verified
- Apr 2026
- Primary completion
- May 31, 2024
- Completion
- May 31, 2024
Study Design
- Enrollment
- 35 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 8 mg DoseOnly 1 eye will be selected as the study eye by the investigator. Patients will receive a single dose utilizing the PFS.
Primary Outcome Measure
Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS [ Time Frame: At Day 1 ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Retina Consultants of Texas | Bellaire | Texas | 77401 | - |
| Retina Consultants of Texas | The Woodlands | Texas | 77385 | - |
Find similar trials in Bellaire, TX
Related Studies
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMDEnrolling By Invitation · AbbVie · Phoenix, Arizona
- A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular DegenerationPHASE3 · Not Yet Recruiting · Rophibio, Inc. · Phoenix, Arizona
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPHASE3 · Recruiting · 4D Molecular Therapeutics · Scottsdale, Arizona
- CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DMEPHASE3 · Recruiting · EyePoint Pharmaceuticals, Inc. · Gilbert, Arizona